Despite the multiple system involvement, an association between 22q11.2 deletion syndrome and Parkinson's disease was not suspected until the publication of independent case reports of cooccurrence of parkinsonism in patients with 22q11.2 deletion syndrome.
2,3 Interest in this possible link increased after Butcher and colleagues 4 reported four patients with early-onset Parkinson's disease in their study of 159 adults with 22q11.2 deletion syndrome. They found that the use of antipsychotics in these patients delayed diagnosis of Parkinson's disease by up to a decade and typical Lewy bodies were present in two of three patients at post mortem. All of the nine reported cases with 22q11.2 deletion syndrome in the published work so far had age at onset of Parkinson's disease of younger than 50 years. [4] [5] [6] In The Lancet Neurology, Kin Mok and colleagues 5 examined the opposite association; that is, they looked for deletions at 22q11.2 in four independent case-control Parkinson's disease d atasets from diff erent European populations. They did array-based copy number variation analyses of data from 9387 patients with Parkinson's disease and 13 863 controls. They found a signifi cant increase of the common 3 Mb deletion (associated with 22q11.2 deletion syndrome) in Parkinson's disease (eight cases) compared with controls (no cases; p=0·00082). The deletions were associated with disease age at onset, with 0·49% frequency in patients with early-onset Parkinson's disease (<45 years) compared with 0·04% frequency in those with an age of onset of 45 years or older (p=0·005). These fi ndings corroborate those from previous case reports 2,3 and provide further support for an association between 22q11.2 deletion syndrome and Parkinson's disease, especially in patients with early-onset disease. Although an association does not prove causality, it provides impetus to look for a novel Parkinson's disease gene within the deleted region.
Missense mutations of pathogenic genes have been well described in Parkinson's disease. 6, 7 Additionally, copy number variants involving recessive (eg, PARKIN, PINK1) and dominant genes (SNCA) have also been implicated in familial Parkinson's disease. Whether haploinsuffi ciency of a single gene or a group of genes in the 22q11.2 region is responsible for the development of Parkinson's disease remains unknown. This could be investigated by knocking down individual genes or studying the eff ect of deletion mutants in neuronal cultures. Further validation in animal models (ie, gene knockdown) could be done to verify dopaminergic neuronal loss and other pathological features of Parkinson's disease. Deep sequencing of genes in the remaining hemizygous allele to identify mutations might identify novel recessive causative genes, although this might be challenging since these patients generally do not have a positive family history (most are carriers of de-novo mutations). A combination of a deletion and a mutation in the opposite allele or with other epigenetic factors is another possibility. Some of the candidate genes within this region (eg, COMT, DGCR8, and SEPT5) are possible causative genes because of their interaction with known Parkinson's disease genes or dopaminergic pathways.
Although Mok and colleagues highlight the possible clinical eff ects (eg, screening and genetic counselling) of their fi ndings, we should approach their fi ndings with cautious optimism. First, both the estimated prevalence of 22q11.2 deletion syndrome in the general population (0·024%) and that of a 22q deletion among patients with early-onset Parkinson's disease (0·49%) are low. Hence, any large-scale eff ect on screening in the general population of patients with Parkinson's disease will be small. Second, including the present study, the number of patients identifi ed with coexistent 22q11.2 deletion syndrome and Parkinson's disease is still low (<20). Phenotype characterisation of these patients is still scarce. Three of the six cases in the present study had previous psychiatric or cognitive problems, but these diagnoses seemed to be based on historical information, and comprehensive neuropsychological testing, systematic screening, and details regarding treatment complications were not available. Third, we do not know why only 3% of patients with 22q11.2 deletion syndrome develop Parkinson's disease 6 and whether there are any specifi c clinically useful warning signs and factors that might aff ect penetrance in patients who might develop parkinsonian symptoms subsequently.
Despite many missing connections in the pathophysiological link between 22q11.2 deletion syndrome and Parkinson's disease, the present study will certainly raise clinicians' awareness and heighten their vigilance in looking for features of 22q11.2 deletion syndrome in patients with early-onset Parkinson's disease, and carefully considering Parkinson's disease as a diff erential diagnosis in patients with 22q11.2 deletion syndrome even if these patients are on antipsychotic drugs. Further functional experiments, replication studies in independent clinical cohorts, and identifi cation of additional cases with chromosomal deletion sizes other than the 3 Mb region will shed more light on this interesting association. Treating neurodegenerative disease before illness: a challenge for the 21st century
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Clinicians have long recognised that pathological processes can impair organ function before clinical signs emerge, especially in chronic illness. Cardiac myocytes and renal tubular epithelial cells are thought to dwindle well in advance of overt clinical signs of cardiac and renal failure. Furthermore, often in retrospect, patients recognise that non-specifi c or subtle symptoms and signs (eg, fatigue) occurred before more overt features of illness such as pedal oedema or dyspnoea. Evidence that elevated systolic blood pressure, serum glucose, and cholesterol concentrations are clinically silent-but readily measurable-risks for serious illnesses (stroke, blindness, renal failure, etc) has led to treatments that have strikingly reduced the burden of chronic illnesses. The discovery of biomarkers for HIV infection (viral load or CD4 cell count) fuelled the development of therapies that transformed an acutely lethal illness into one with a manageable clinical course. These experiences have led many investigators to think that devastating neurodegenerative diseases might also be treatable before any overt signs of illness arise; David Salat and colleagues 1 propose such a concept for Parkinson's disease in The Lancet Neurology. This notion is fuelled by an increasing understanding of pathological processes and improved insight into clinical phenomena that, although non-specifi c, might herald or actually represent the active neurodegenerative process in Parkinson's disease (eg, constipation or rapid eye movement sleep disorder). Such hope, however, should be tempered by present research constraints.
Parkinson's disease is usually sporadic, although some important genetic cohorts are now recognised. In autosomal-dominant disorders such as Huntington's disease and dominantly inherited Alzheimer's disease, there is certainty about risk of illness, but uncertainty about its timing. By contrast, in idiopathic illnesses such as sporadic Parkinson's disease, we have to rely on non-specifi c preclinical markers such as constipation to predict disease risk. This reliance is confounded by the fact that only a minority of prodromal Parkinson's disease patients have constipation, and the majority of individuals with constipation will never have Parkinson's disease. Sorting of the population into a more refi ned risk cohort (as Salat and colleagues propose) will require greater refi nement of additional biomarkers, whether biological fl uid or neuroimaging based. Exposure of individuals to treatment for prevention of an illness that they are not destined to develop is not justifi able, and hence clarity on disease defi nition is essential.
Establishing adequate outcomes in clinical trials is an additional challenge. The best outcome would be that nothing happens (ie, that illness never emerges). This scenario presents some diffi culties, because no disease will also be the outcome if researchers mistakenly identify and recruit into trials a group not truly at risk. Moreover, disease onset is an outcome that can take long follow-up periods to observe. Many research participants might be reluctant to continue in long studies, on treatment, with no hope of improvement (because they are well to begin with) and few interim rewards (such as low cholesterol concentrations or glycosylated haemoglobin score) for continued participation. Furthermore, participation itself might stigmatise participants, or remind them of their risk status and perceived poor level of health compared with their peers.
The assessment of disease onset also presents methodological challenges; previous masked studies of at-risk cohorts in Huntington's disease have reported
